Navigation Links
EquitiesIQ Initiates Coverage of Alliqua, Inc.
Date:1/14/2014

New York, NY (PRWEB) January 14, 2014

EquitiesIQ, a leading informational research provider, has initiated coverage of Alliqua, Inc. (OTCQB: ALQA). Alliqua is an emerging biomedical company acquiring, developing, manufacturing, and marketing proprietary products to serve the wound care market.

Free report download: http://equitiesiq.com/reports/alliqua/

In late 2012, Alliqua was restructured with a seasoned management team and Board, which launched the company’s new strategy to become a leading provider of wound care products. Coincident with the new leadership, Alliqua raised capital from company insiders along with a group of retail and institutional investors. With this initial capital, Alliqua began to build its sales infrastructure and consolidate its operations.

Throughout 2013, the company entered strategic relationships with a variety of wholesale distributors including Team Distribution International, World Health Industries, McKesson Medical-Surgical, and Medline. Alliqua also secured a license agreement with sorbion GmbH & Co. to distribute wound care dressings based on sorbion’s proprietary hydroactive technology.

In November 2013, the company entered into an agreement with Celgene Corporation (CELG) to develop and market wound healing products based on Celgene Cellular Thereapeutics’ (CCT) placenta-derived technology. Products based on this technology are anticipated to have superior wound-healing characteristics, and will enable Alliqua to enter one of the fastest growing segments of the wound care market. In conjunction with the Celgene license agreement, a group of healthcare-focused institutional investors, and Celgene itself, collectively made a $14 million equity investment into the company.

Well capitalized, with its own line of value-added hydrogels, the sorbion wound
'/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
2. Baxter Initiates Phase I Clinical Trial of Longer-acting Recombinant FVIII Treatment for Hemophilia A
3. Research Alert -- Empire Asset Management Co. Initiates Coverage on Exact Sciences (NASDAQ: EXAS)
4. Applied Genetics Initiates Commercial Operation
5. Snoasis Medical Initiates Distribution in Japan Through Hausten Healthcare
6. Medbox, Inc. Initiates "Responsible Consumption" Campaign for Marijuana in Recreational States
7. Shire Regenerative Medicine Initiates Phase 3 Study of ABH001 for Patients with Epidermolysis Bullosa
8. ADVENTRX Initiates Thorough QT/QTc Clinical Study Of ANX-188
9. Advanced Cell Diagnostics Initiates Agreement to Study Biomarkers for Cancer Immunotherapy
10. NewLink Genetics Initiates Phase 2 Trial of IDO Pathway Inhibitor, Indoximod, for the Treatment of Metastatic Breast Cancer
11. MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... CA (PRWEB) October 30, 2014 ... today that they have manually curated public data source ... non profit customers. the data is now available ... curates and unifies public and internal data sources for ... and knowledge out of the data that becomes more ...
(Date:10/30/2014)... (PRWEB) October 30, 2014 Spartan Bioscience ... Spartan RX CYP2C19 System . It detects CYP2C19 genetic ... cheek swab. , The Spartan RX CYP2C19 System is ... has been approved in Canada. Due to the system’s ... may be used by healthcare professionals such as doctors, ...
(Date:10/30/2014)... Avure Technologies celebrates a year of success and ... its fleet of high volume High Pressure Processing (HPP) systems. ... return to PackExpo this year, which is where we first ... Jeff Williams, CEO at Avure. “Sales of the new Avure ... meeting the challenges of market demand for higher throughput. We ...
(Date:10/30/2014)... 2014 Isis Pharmaceuticals, Inc. (NASDAQ: ISIS ... will present a company overview at the Nomura Biotechnology Conference ... Boston, MA. A live ... & Media" section of the Company,s website, www.isispharm.com .  ... 48 hours and will be archived for a limited time. ...
Breaking Biology Technology:Rancho BioSciences Manually Curated TCGA Data Sets Available 2Health Canada approves first near-patient DNA test for personalized medicine 2Health Canada approves first near-patient DNA test for personalized medicine 3In High Demand: New High Pressure Processing (HPP) System with Maximum Throughput Drives Strong Sales 2In High Demand: New High Pressure Processing (HPP) System with Maximum Throughput Drives Strong Sales 3Isis Pharmaceuticals to Present at the Nomura Biotechnology Conference 2
... BRUNSWICK, N.J. and NANJING, China, Sept. 3 ,Acesys ... combining the drug discovery expertise and project management,capabilities ... chemistry resources and,favorable cost structure of Acesys in ... alliance will encompass all,aspects of medicinal chemistry for ...
... strategic planner for an organization in the filter industry? ... Are you part of a filter company looking ... the growth segments in the filter and filtration markets. ... Place in Charlotte, NC, the American Filtration and Separations ...
... HOBOKEN, N.J. - Dr. Yong Shi of Stevens ... grant for his project titled "MEMS Umbrella-Shaped Actuator ... was approved on scientific/technical merit for three years ... the research is to design, fabricate and test ...
Cached Biology Technology:Acesys and Provid Announce Alliance for Medicinal Chemistry Services 2Filter Markets - Discover the Growth Segments 2Filter Markets - Discover the Growth Segments 3Dr. Yong Shi awarded NSF grant 2
(Date:10/31/2014)... Bugnyar and his team have been studying the ... Northern Austrian Alps for years. They observed that ... as grooming and playing. However, they also observed ... a third individual. Although in about 50 % ... broke up the two affiliating ravens, intervening can ...
(Date:10/30/2014)... When most animals begin life, cells immediately begin accepting ... organ. However, mammals, including humans, are special. The cells ... choice – to become the protective placenta or to ... critical first step that research from Michigan State University ... current issue of PLOS Genetics , ...
(Date:10/30/2014)... developed a suite of technologies that can be used ... applications in everything from search and rescue to service ... platform for computer-mediated communication between humans and dogs that ... behavioral signals and sending them clear and unambiguous cues ... of computer science at NC State and co-lead author ...
Breaking Biology News(10 mins):Identifying the source of stem cells 2New tech aims to improve communication between dogs and humans 2
... release is available in Spanish . ... However, human nutrition researchers agree that many questions remain about ... Studies led by Agricultural Research Service (ARS) molecular biologist Daniel ... Certain kinds of inflammation can increase risk of cancer ...
... is available in Spanish . Researchers ... the Clinical Hospital San Cecilio and the University Rey Juan ... patients with tension headache improves within 24 hours after receiving ... an increasing incidence in the population. This type of disorder ...
... The ,Geographic Chemicals in Groundwaters and Soils, event ... Marie Curie Research Training Network. This network, coordinated ... to highlight the environmental effect including the effect ... in groundwater and soils. Held today and tomorrow ...
Cached Biology News:Luteolin stars in study of healthful plant compounds 2University of Manchester academics at international conference on geographic chemicals 2
...
Mouse monoclonal antibody raised against a partial recombinant ZNF155. NCBI Entrez Gene ID = ZNF155...
... are macroporous polystyrene beads for hydrophobic interaction ... for adsorbing organics of molecular weight less ... are useful for the adsorption of nonpolar ... the removal of detergents such as Triton ...
... Immunogen : Fusion protein corresponding ... of human Mi-2 Formulation: 0.7M ... 0.035% sodium azide, containing 30% ... by immunoblot on Hela nuclear ...
Biology Products: